SINGLE TRIALS WITH SIZE, POWERFUL STATISTICS OR CORROBATING ENDPOINTS MAY BE CONSIDERED AS SUPPORT FOR NDAs, FDA EXPLAINS IN EFFICACY EVIDENCE GUIDANCE